Growth-phase dependence of susceptibility to antimicrobial peptides in Staphylococcus aureus

Microbiology

Volumn 157, Issue 6, 2011, Pages 1786-1797

  Matsuo, Miki ^a   Oogai, Yuichi ^a   Kato, Fuminori ^b   Sugai, Motoyuki ^b   Komatsuzawa, Hitoshi ^a  

^a KAGOSHIMA UNIVERSITY   (Japan)

^b HIROSHIMA UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; BACTERIAL PROTEIN; DLTC PROTEIN; MPRF PROTEIN; POLYPEPTIDE ANTIBIOTIC AGENT; UNCLASSIFIED DRUG;

ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL GROWTH; CELL SURFACE; CONTROLLED STUDY; GENE INACTIVATION; GENETIC REGULATION; GROWTH CURVE; MOLECULAR SENSOR; MUTANT; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN EXPRESSION; STAPHYLOCOCCUS AUREUS;

AMINOACYLTRANSFERASES; ANTIMICROBIAL CATIONIC PEPTIDES; BACTERIAL PROTEINS; CARRIER PROTEINS; CELL MEMBRANE; GENE EXPRESSION REGULATION, BACTERIAL; HUMANS; MICROBIAL SENSITIVITY TESTS; MUTATION; QUORUM SENSING; STAPHYLOCOCCUS AUREUS; TRANS-ACTIVATORS;

BACTERIA (MICROORGANISMS); STAPHYLOCOCCUS AUREUS;

EID: 79958166236     PISSN: 13500872     EISSN: None     Source Type: Journal    
DOI: 10.1099/mic.0.044727-0     Document Type: Article

References (54)

1. Abachin, E., Poyart, C., Pellegrini, E., Milohanic, E., Fiedler, F., Berche, P. & Trieu-Cuot, P. (2002). Formation of D-alanyllipoteichoic acid is required for adhesion and virulence of Listeria monocytogenes. Mol Microbiol 43, 1-14.
2. Baba, T., Takeuchi, F., Kuroda, M., Yuzawa, H., Aoki, K., Oguchi, A., Nagai, Y., Iwama, N., Asano, K., Naimi, T., Kuroda, H., Cui, L., Yamamoto, K. & Hiramatsu, K. (2002). Genome and virulence determinants of high virulence community-acquired MRSA. Lancet 359, 1819-1827.
3. Braff, M. H., Jones, A. L., Skerrett, S. J. & Rubens, C. E. (2007). Staphylococcus aureus exploits cathelicidin antimicrobial peptides produced during early pneumonia to promote staphylokinasedependent fibrinolysis. J Infect Dis 195, 1365-1372.
4. Cheung, A. L., Bayer, A. S., Zhang, G., Gresham, H. & Xiong, Y. Q. (2004). Regulation of virulence determinants in vitro and in vivo in Staphylococcus aureus. FEMS Immunol Med Microbiol 40, 1-9.
5. Collins, L. V., Kristian, S. A., Weidenmaier, C., Faigle, M., Van Kessel, K. P., Van Strijp, J. A., Götz, F., Neumeister, B. & Peschel, A. (2002). Staphylococcus aureus strains lacking D-alanine modifications of teichoic acids are highly susceptible to human neutrophil killing and are virulence attenuated in mice. J Infect Dis 186, 214-219.
6. Cunliffe, R. N. (2003). Alpha-defensins in the gastrointestinal tract. Mol Immunol 40, 463-467.
7. Deurenberg, R. H., Vink, C., Kalenic, S., Friedrich, A. W., Bruggeman, C. A. & Stobberingh, E. E. (2007). The molecular evolution of methicillin-resistant Staphylococcus aureus. Clin Microbiol Infect 13, 222-235.
8. Fellermann, K., Wehkamp, J., Herrlinger, K. R. & Stange, E. F. (2003a). Crohn's disease: a defensin deficiency syndrome? Eur J Gastroenterol Hepatol 15, 627-634.
9. Fellermann, K., Wehkamp, J. & Stange, E. F. (2003b). Antimicrobial peptides in the skin. N Engl J Med 348, 361-363, author reply 361-363.
10. Foster, T. J. (2004). The Staphylococcus aureus "superbug". J Clin Invest 114, 1693-1696.
11. Foster, T. J. (2005). Immune evasion by staphylococci. Nat Rev Microbiol 3, 948-958.
12. Ganz, T. & Lehrer, R. I. (1995). Defensins. Pharmacol Ther 66, 191-205.
13. Ganz, T., Selsted, M. E., Szklarek, D., Harwig, S. S., Daher, K., Bainton, D. F. & Lehrer, R. I. (1985). Defensins. Natural peptide antibiotics of human neutrophils. J Clin Invest 76, 1427-1435.
14. Geisinger, E., Adhikari, R. P., Jin, R., Ross, H. F. & Novick, R. P. (2006). Inhibition of rot translation by RNAIII, a key feature of agr function. Mol Microbiol 61, 1038-1048.
15. Gottenbos, B., Grijpma, D. W., van der Mei, H. C., Feijen, J. & Busscher, H. J. (2001). Antimicrobial effects of positively charged surfaces on adhering Gram-positive and Gram-negative bacteria. J Antimicrob Chemother 48, 7-13.
16. Gross, M., Cramton, S. E., Götz, F. & Peschel, A. (2001). Key role of teichoic acid net charge in Staphylococcus aureus colonization of artificial surfaces. Infect Immun 69, 3423-3426.
17. Grundmann, H., Aires-de-Sousa, M., Boyce, J. & Tiemersma, E. (2006). Emergence and resurgence of meticillin-resistant Staphylococcus aureus as a public-health threat. Lancet 368, 874-885.
18. Howden, B. P., Stinear, T. P., Allen, D. L., Johnson, P. D., Ward, P. B. & Davies, J. K. (2008). Genomic analysis reveals a point mutation in the two-component sensor gene graS that leads to intermediate vancomycin resistance in clinical Staphylococcus aureus. Antimicrob Agents Chemother 52, 3755-3762.
19. Huntzinger, E., Boisset, S., Saveanu, C., Benito, Y., Geissmann, T., Namane, A., Lina, G., Etienne, J., Ehresmann, B. & other authors (2005). Staphylococcus aureus RNAIII and the endoribonuclease III coordinately regulate spa gene expression. EMBO J 24, 824-835.
20. Jin, T., Bokarewa, M., Foster, T., Mitchell, J., Higgins, J. & Tarkowski, A. (2004). Staphylococcus aureus resists human defensins by production of staphylokinase, a novel bacterial evasion mechanism. J Immunol 172, 1169-1176.
21. Komatsuzawa, H., Ohta, K., Fujiwara, T., Choi, G. H., Labischinski, H. & Sugai, M. (2001). Cloning and sequencing of the gene, fmtC, which affects oxacillin resistance in methicillin-resistant Staphylococcus aureus. FEMS Microbiol Lett 203, 49-54.
22. Komatsuzawa, H., Fujiwara, T., Nishi, H., Yamada, S., Ohara, M., McCallum, N., Berger-Bächi, B. & Sugai, M. (2004). The gate controlling cell wall synthesis in Staphylococcus aureus. Mol Microbiol 53, 1221-1231.
23. 2 against Staphylococcus aureus. J Biol Chem 277, 47636-47644.
24. Kraus, D., Herbert, S., Kristian, S. A., Khosravi, A., Nizet, V., Götz, F. & Peschel, A. (2008). The GraRS regulatory system controls Staphylococcus aureus susceptibility to antimicrobial host defenses. BMC Microbiol 8, 85.
25. Kreiswirth, B. N., Löfdahl, S., Betley, M. J., O'Reilly, M., Schlievert, P. M., Bergdoll, M. S. & Novick, R. P. (1983). The toxic shock syndrome exotoxin structural gene is not detectably transmitted by a prophage. Nature 305, 709-712.
26. Kristian, S. A., Datta, V., Weidenmaier, C., Kansal, R., Fedtke, I., Peschel, A., Gallo, R. L. & Nizet, V. (2005). D-Alanylation of teichoic acids promotes group A Streptococcus antimicrobial peptide resistance, neutrophil survival, and epithelial cell invasion. J Bacteriol 187, 6719-6725.
27. Larrick, J. W., Hirata, M., Balint, R. F., Lee, J., Zhong, J. & Wright, S. C. (1995). Human CAP18: a novel antimicrobial lipopolysaccharidebinding protein. Infect Immun 63, 1291-1297.
28. Lehrer, R. I. & Ganz, T. (1999). Antimicrobial peptides in mammalian and insect host defence. Curr Opin Immunol 11, 23-27.
29. Li, M., Cha, D. J., Lai, Y., Villaruz, A. E., Sturdevant, D. E. & Otto, M. (2007a). The antimicrobial peptide-sensing systemaps of Staphylococcus aureus. Mol Microbiol 66, 1136-1147.
30. Li, M., Lai, Y., Villaruz, A. E., Cha, D. J., Sturdevant, D. E. & Otto, M. (2007b). Gram-positive three-component antimicrobial peptidesensing system. Proc Natl Acad Sci U S A 104, 9469-9474.
31. Lowy, F. D. (1998). Staphylococcus aureus infections. N Engl J Med 339, 520-532.
32. Luong, T. T. & Lee, C. Y. (2006). The arl locus positively regulates Staphylococcus aureus type 5 capsule via an mgrA-dependent pathway. Microbiology 152, 3123-3131.
33. Manders, S. M. (1998). Toxin-mediated streptococcal and staphylococcal disease. J Am Acad Dermatol 39, 383-398, quiz 399-400.
34. Matsuo, M., Kato, F., Oogai, Y., Kawai, T., Sugai, M. & Komatsuzawa, H. (2010). Distinct two-component systems in methicillin-resistant Staphylococcus aureus can change the susceptibility to antimicrobial agents. J Antimicrob Chemother 65, 1536-1537.
35. Meehl, M., Herbert, S., Götz, F. & Cheung, A. (2007). Interaction of the GraRS two-component system with the VraFG ABC transporter to support vancomycin-intermediate resistance in Staphylococcus aureus. Antimicrob Agents Chemother 51, 2679-2689.
36. Midorikawa, K., Ouhara, K., Komatsuzawa, H., Kawai, T., Yamada, S., Fujiwara, T., Yamazaki, K., Sayama, K., Taubman, M. A. & other authors (2003). Staphylococcus aureus susceptibility to innate antimicrobial peptides, beta-defensins and CAP18, expressed by human keratinocytes. Infect Immun 71, 3730-3739.
37. Morfeldt, E., Taylor, D., von Gabain, A. & Arvidson, S. (1995). Activation of alpha-toxin translation in Staphylococcus aureus by the trans-encoded antisense RNA, RNAIII. EMBO J 14, 4569-4577.
38. Novick, R. P. (2003). Autoinduction and signal transduction in the regulation of staphylococcal virulence. Mol Microbiol 48, 1429-1449.
39. Novick, R. P. & Geisinger, E. (2008). Quorum sensing in staphylococci. Annu Rev Genet 42, 541-564.
40. Ong, P. Y., Ohtake, T., Brandt, C., Strickland, I., Boguniewicz, M., Ganz, T., Gallo, R. L. & Leung, D. Y. (2002). Endogenous antimicrobial peptides and skin infections in atopic dermatitis. N Engl J Med 347, 1151-1160.
41. Ouhara, K., Komatsuzawa, H., Kawai, T., Nishi, H., Fujiwara, T., Fujiue, Y., Kuwabara, M., Sayama, K., Hashimoto, K. & Sugai, M. (2008). Increased resistance to cationic antimicrobial peptide LL-37 in methicillin-resistant strains of Staphylococcus aureus. J Antimicrob Chemother 61, 1266-1269.
42. Peschel, A., Otto, M., Jack, R. W., Kalbacher, H., Jung, G. & Götz, F. (1999). Inactivation of the dlt operon in Staphylococcus aureus confers sensitivity to defensins, protegrins, and other antimicrobial peptides. J Biol Chem 274, 8405-8410.
43. Peschel, A., Jack, R. W., Otto, M., Collins, L. V., Staubitz, P., Nicholson, G., Kalbacher, H., Nieuwenhuizen, W. F., Jung, G. & other authors (2001). Staphylococcus aureus resistance to human defensins and evasion of neutrophil killing via the novel virulence factor MprF is based on modification of membrane lipids with L-lysine. J Exp Med 193, 1067-1076.
44. Poyart, C., Pellegrini, E., Marceau, M., Baptista, M., Jaubert, F., Lamy, M. C. & Trieu-Cuot, P. (2003). Attenuated virulence of Streptococcus agalactiae deficient in D-alanyl-lipoteichoic acid is due to an increased susceptibility to defensins and phagocytic cells. Mol Microbiol 49, 1615-1625.
45. Pütsep, K., Carlsson, G., Boman, H. G. & Andersson, M. (2002). Deficiency of antibacterial peptides in patients with morbus Kostmann: an observation study. Lancet 360, 1144-1149.
46. Ramanathan, B., Davis, E. G., Ross, C. R. & Blecha, F. (2002). Cathelicidins: microbicidal activity, mechanisms of action, and roles in innate immunity. Microbes Infect 4, 361-372.
47. Rooijakkers, S. H., van Kessel, K. P. & van Strijp, J. A. (2005). Staphylococcal innate immune evasion. Trends Microbiol 13, 596-601.
48. Sau, S., Sun, J. & Lee, C. Y. (1997). Molecular characterization and transcriptional analysis of type 8 capsule genes in Staphylococcus aureus. J Bacteriol 179, 1614-1621.
49. Selsted, M. E. & Ouellette, A. J. (2005). Mammalian defensins in the antimicrobial immune response. Nat Immunol 6, 551-557.
50. Sieprawska-Lupa, M., Mydel, P., Krawczyk, K., Wójcik, K., Puklo, M., Lupa, B., Suder, P., Silberring, J., Reed, M. & other authors (2004). Degradation of human antimicrobial peptide LL-37 by Staphylococcus aureus-derived proteinases. Antimicrob Agents Chemother 48, 4673-4679.
51. Wehkamp, J., Fellermann, K., Herrlinger, K. R., Baxmann, S., Schmidt, K., Schwind, B., Duchrow, M., Wohlschläger, C., Feller, A. C. & Stange, E. F. (2002). Human beta-defensin 2 but not betadefensin 1 is expressed preferentially in colonic mucosa of inflammatory bowel disease. Eur J Gastroenterol Hepatol 14, 745-752.
52. Yang, S. J., Xiong, Y. Q., Dunman, P. M., Schrenzel, J., François, P., Peschel, A. & Bayer, A. S. (2009a). Regulation of mprF in daptomycinnonsusceptible Staphylococcus aureus strains. Antimicrob Agents Chemother 53, 2636-2637.
53. Yang, S. J., Kreiswirth, B. N., Sakoulas, G., Yeaman, M. R., Xiong, Y. Q., Sawa, A. & Bayer, A. S. (2009b). Enhanced expression of dltABCD is associated with the development of daptomycin nonsusceptibility in a clinical endocarditis isolate of Staphylococcus aureus. J Infect Dis 200, 1916-1920.
54. Zaiou, M. & Gallo, R. L. (2002). Cathelicidins, essential gene-encoded mammalian antibiotics. J Mol Med 80, 549-561.